We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Sanofi | NASDAQ:SNY | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.46 | -0.93% | 49.00 | 49.02 | 49.93 | 49.595 | 48.97 | 49.48 | 1,113,911 | 22:58:03 |
From May 2019 to May 2024
PARIS--French drugmaker Sanofi (SAN.FR) said Monday it has entered into an agreement to develop cancer immunotherapies with German biotech company Evotec AG (EVT.XE) and Austria's Apeiron Biologics.
The deal covers research collaboration and a license agreement to discover and develop molecule-based immuno-oncology therapies that treat cancers by boosting the anti-tumor activity of the human immune system, Sanofi said.
Sanofi will have sole responsibility for all development, regulatory, commercial and manufacturing activities of the products. The French pharmaceutical group will provide two years of funding for Evotec and Apeiron. If the project continues, Evotec will be entitled to receive further milestone payments that could total more than EUR200 million, as well as royalties on net sales, Sanofi said.
-Write to William Horobin at william.horobin@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
